Patients with type 2 diabetes treated with sodium-glucose cotransporter-2 (SGLT-2) inhibitors have a significantly lower risk of developing dementia and Alzheimer's disease than those receiving ...
SGLT2 inhibitors showed significantly improved mortality benefits compared with DPP-4 inhibitors in patients with diabetic kidney disease (DKD) in a large target trial emulation study that adds ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results